Skip to main content Skip to main navigation menu Skip to site footer

Body mass index and total testosterone level in obese male pre-diabetic patients: correlation with homeostasis model assessment of insulin resistance

  • Eva Decroli ,
  • Dinda Aprilia ,
  • Alexander Kam ,
  • Afdol Rahmadi ,


Link of Video Abstract:


Introduction: Men with comorbidities are typically more likely to have testosterone insufficiency. In this study, total testosterone levels in obese male pre-diabetic patients will be correlated with body mass index and a homeostasis model assessment of insulin resistance (HOMA-IR).

Methods: This investigation is a cross-sectional analytical observational study. Insulin resistance was measured by HOMA-IR. Enzyme link immunosorbent assay (ELISA) was used to measure the total testosterone levels. 35 obese male patients who were also pre-diabetic had these signs evaluated.

Results: In this study, 35 obese male individuals with a family history of type 2 diabetes mellitus and an average age of 31.91 were included (3.79). The total testosterone level was 328.72 (94.94), the mean BMI was 33.12 (4.11) kg/m2, the HOMA-IR was 3.64 (1.00), and testosterone levels were lowered (300 ng/dl) in 48% of the individuals. In male pre-diabetic individuals, there was a strong negative connection between BMI and Total Testosterone levels (r = -0.567, p=0.001). In male pre-diabetic patients, there was a significant negative connection between HOMA-IR and total testosterone levels (r = -0.671, p=0.001).

Conclusion: In pre-diabetic obese male patients, there was a strong inverse relationship between total testosterone level and BMI. In obese male pre-diabetic individuals, there is a substantial negative association between HOMA-IR and total testosterone level.


  1. Traish AM. Benefits and Health Implications of Testosterone Therapy in Men With Testosterone Deficiency. Sex Med Rev. 2018;6(1):86–105. doi: 10.1016/j.sxmr.2017.10.001.
  2. Li Y, Zhang M, Liu X, Cui W, Rampersad S, Li F, et al. Correlates and prevalence of hypogonadism in patients with early- and late-onset type 2 diabetes. Andrology. 2017;5(4):739–43. doi: 10.1111/andr.12360.
  3. Ross A, Bhasin S. Hypogonadism: Its Prevalence and Diagnosis. Urol Clin North Am. 2016;43(2):163–76. doi: 10.1016/j.ucl.2016.01.002.
  4. Haring R, Ittermann T, Völzke H, Krebs A, Zygmunt M, Felix SB, et al. Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: Results from the study of health in Pomerania. Aging Male. 2010;13(4):247–57. doi: 10.3109/13685538.2010.487553.
  5. Anaissie J, DeLay KJ, Wang W, Hatzichristodoulou G, Hellstrom WJ. Testosterone deficiency in adults and corresponding treatment patterns across the globe. Transl Androl Urol. 2017;6(2):183–91. doi: 10.21037/tau.2016.11.16.
  6. Baillargeon J, Urban RJ, Zhang W, Zaiden MF, Javed Z, Sheffield-Moore M, et al. Testosterone replacement therapy and hospitalization rates in men with COPD. Chron Respir Dis. 2018;16. doi: 10.1177/1479972318793004.
  7. Yassin A, Haider A, Haider KS, Caliber M, Doros G, Saad F, et al. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: Eight-year data from a registry study. Diabetes Care. 2019;42(6):1104–11. doi: 10.2337/dc18-2388.
  8. Lyssenko V, Laakso M. Genetic screening for the risk of type 2 diabetes: Worthless or valuable? Diabetes Care. 2013;36(SUPPL.2). doi: 10.2337/dcS13-2009.
  9. Aamir AH, Ul-Haq Z, Mahar SA, Qureshi FM, Ahmad I, Jawa A, et al. Diabetes prevalence survey of Pakistan (DPS-PAK): Prevalence of type 2 diabetes mellitus and prediabetes using HbA1c: A population-based survey from Pakistan. BMJ Open. 2019;9(2):1–9. doi: 10.1136/bmjopen-2018-025300.
  10. Rooney MR, Fang M, Ogurtsova K, Ozkan B, Echouffo-Tcheugui JB, Boyko EJ, Magliano DJ, Selvin E. Global Prevalence of Prediabetes. Diabetes Care. 2023;46(7):1388-1394. doi: 10.2337/dc22-2376.
  11. Rajput R, Banerjee S. Prevalence of adult-onset hypogonadism and erectile dysfunction in males with prediabetes. Int J Diabetes Metab. 2018;2–7. doi: 10.1159/000492477.
  12. Boeri L, Capogrosso P, Ventimiglia E, Pederzoli F, Frego N, Cazzaniga W, et al. Undiagnosed prediabetes is highly prevalent in primary infertile men – results from a cross-sectional study. BJU Int. 2019;123(6):1070–7. doi: 10.1111/bju.14558.
  13. Sinha N, Maiti A, Sinha A, Basu AK, Das TC. Study of serum testosterone level in males with prediabetes, before and after 3 months of metformin therapy, in patients attending a tertiary care hospital in West Bengal, Eastern India.JMSCR.2019;7(1)32-43. doi: 10.18535/jmscr/v7i1.06.
  14. Gupta AK, Menon A, Brashear M, Johnson WD. Prediabetes: prevalence, pathogenesis, and recognition of enhanced risk. Second Edition. Nutritional and therapeutic interventions for diabetes and metabolic syndrome. Elsevier Inc.; 2012. 57–75. doi: 10.1016/B978-0-12-385083-6.00005-X.
  15. Ho CH, Yu HJ, Wang CY, Jaw FS, Hsieh JT, Liao WC, et al. Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome. PLoS One. 2013;8(9):1–9. doi: 10.1371/journal.pone.0074173.
  16. Osuna C JA, Gómez-Pérez R, Arata-Bellabarba G, Villaroel V. Relationship between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and insulin resistance in obese men. Arch Androl. 2006;52(5):355–61. doi: 10.1080/01485010600692017.
  17. Chen L, Xie Y-M, Pei J-H, Kuang J, Chen H-M, Chen Z, et al. Sugar-sweetened beverage intake and serum testosterone levels in adult males 20-39 years old in the United States. Reprod Biol Endocrinol. 2018;16(1):1–7. doi: 10.1186/s12958-018-0378-2.
  18. Kahn BE, Brannigan RE. Obesity and male infertility. Curr Opin Urol. 2017;27(5):441–5. doi: 10.1097/MOU.0000000000000417.
  19. Vargatu I. Williams textbook of endocrinology. Vol. 12, Acta Endocrinologica (Bucharest). 2016. 113–113. doi: 10.4183/aeb.2016.113.
  20. Lee DM, O’Neill TW, Pye SR, Silman AJ, Finn JD, Pendleton N, et al. The European male aging study (EMAS): Design, methods, and recruitment. Int J Androl. 2009;32(1):11–24. doi: 10.1111/j.1365-2605.2008.00879.x.
  21. Fernandez CJ, Chacko EC, Pappachan JM. Male obesity-related secondary hypogonadism – pathophysiology, clinical implications, and Management. Eur Endocrinol. 2019;15(2):83–90. doi: 10.17925/EE.2019.15.2.83.
  22. Sedliak M, Kralik M, Cvecka J, Buzgo G, Putala M, Ukropcova B, et al. Relation between testosterone levels and body composition, physical functioning and selected biochemical parameters in adult males. Vnitr lek. 2020;66(2):e37–42. doi: 10.36290/vnl.2020.039.
  23. Valsaraj R, Sengupta N, Baidya A, Goswami S, Sahana PK. Relationship between testosterone, insulin resistance, inflammatory markers and obesity parameters in overweight and obese adolescents and adult males - a cross-sectional study. J Evid Based Med Healthc. 2021;8(13):823–9. doi: 10.18410/jebmh/2021/161.
  24. Diniz MFHS, Beleigoli AMR, Schmidt MI, Duncan BB, Ribeiro ALP, Vidigal PG, Benseñor IM, Lotufo PA, Santos IS, Griep RH, Barreto SM. Homeostasis model assessment of insulin resistance (HOMA-IR) and metabolic syndrome at baseline of a multicentric Brazilian cohort: ELSA-Brasil study. Cad Saude Publica. 2020;36(8):e00072120. doi: 10.1590/0102-311X00072120.
  25. Decroli E, Kam A, Dillasamola. The percentage of depressive symptoms in patients with type 2 diabetes mellitus in M. Djamil General Hospital Padang, Indonesia. J Res Pharm. 2019;23(2):292 – 297. doi: 10.12991/jrp.2019.136
  26. Mulyani WRW, Sanjiwani MID, Sandra, Prabawa IPY, Lestari AAW, Wihandani DM, Suastika K, Saraswati MR, Bhargah A, Manuaba IBAP. Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2020 ;13:559-568. doi: 10.2147/DMSO.S232133.
  27. Artha IMJR, Bhargah A, Dharmawan NK, Pande UW, Triyana KA, Mahariski PA, Yuwono J, Bhargah V, Prabawa IPY, Manuaba IBAP, Rina IK. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus. Vasc Health Risk Manag. 2019;15:149-157. doi: 10.2147/VHRM.S209830.
  28. Handoyo V, Pertiwi GAR, Prabawa IPY, Manuaba IBAP, Bhargah A, Budiana IPG. Management of ST-elevation myocardial infarction in the setting of anterior epistaxis: focused on antiplatelet and antithrombotic therapies. Int Med Case Rep J. 2019;12:33-38. doi: 10.2147/IMCRJ.S189370.
  29. Artha IMJR, Bakta IM, Manuaba IBP, Wita IW, Rohman MS, Astawa INM, Bhargah A. The Effects of Percutaneous Coronary Intervention on Biomarkers and Quality of Life in Patients With Chronic Total Coronary Artery Obstruction. Cardiol Res. 2023;14(1):69-78. doi: 10.14740/cr1455.

How to Cite

Decroli, E. ., Aprilia, D., Kam, A., & Rahmadi, A. (2024). Body mass index and total testosterone level in obese male pre-diabetic patients: correlation with homeostasis model assessment of insulin resistance. Bali Medical Journal, 13(1), 427–430.